BioArctic AB (publ) (BRCTF)
OTCMKTS · Delayed Price · Currency is USD
33.14
0.00 (0.00%)
Feb 11, 2026, 4:00 PM EST
BioArctic AB Employees
BioArctic AB had 122 employees as of September 30, 2025. The number of employees increased by 18 or 17.31% compared to the same quarter last year.
Employees
122
Change
18
Growth
17.31%
Revenue / Employee
$1,666,965
Profits / Employee
$869,612
Market Cap
3.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 122 | 18 | 17.31% |
| Jun 30, 2025 | 119 | 23 | 23.96% |
| Mar 31, 2025 | 116 | 26 | 28.89% |
| Dec 31, 2024 | 107 | 19 | 21.59% |
| Sep 30, 2024 | 104 | 21 | 25.30% |
| Jun 30, 2024 | 96 | 21 | 28.00% |
| Mar 31, 2024 | 90 | 21 | 30.43% |
| Dec 31, 2023 | 88 | 27 | 44.26% |
| Sep 30, 2023 | 83 | 27 | 48.21% |
| Jun 30, 2023 | 75 | 19 | 33.93% |
| Mar 31, 2023 | 69 | 14 | 25.45% |
| Dec 31, 2022 | 61 | 12 | 24.49% |
| Sep 30, 2022 | 56 | 7 | 14.29% |
| Jun 30, 2022 | 56 | 9 | 19.15% |
| Mar 31, 2022 | 55 | 8 | 17.02% |
| Dec 31, 2021 | 49 | 4 | 8.89% |
| Sep 30, 2021 | 49 | 4 | 8.89% |
| Jun 30, 2021 | 47 | 2 | 4.44% |
| Mar 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
BioArctic AB News
- 6 days ago - Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 - PRNewsWire
- 2 months ago - Leqembi included in China's commercial insurance innovative drug list - PRNewsWire
- 2 months ago - New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment - PRNewsWire
- 2 months ago - Eisai Announces Filing Of New Drug Application For Leqembi In Japan - Nasdaq
- 3 months ago - New data on lecanemab to be presented at CTAD conference - PRNewsWire
- 3 months ago - BioArctic AB (publ) 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 3 months ago - Leqembi® approved for IV maintenance treatment in the United Kingdom - PRNewsWire
- 3 months ago - BioArctic AB (publ) (BRCTF) Q3 2025 Earnings Call Transcript - Seeking Alpha